Daybue (Trofinetide) Patent Expiration, LOE Window & CMS Spending
Daybue (Trofinetide) by Acadia Pharmaceuticals: FDA Orange Book core substance LOE 2043-01-12, 0 AB generics, $262.0M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Acadia Pharmaceuticals |
| FDA Application & Pathway | N217026 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2043-01-12 |
| Last Listed Patent or Exclusivity Date | 2043-01-12 |
| Orange Book Patents (*PED Extensions) | 8 patents (4 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $262.0M |
| 2024 Medicare Part D Spend | $39.6M |
| 2024 Medicaid Spend | $222.4M |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 16.1% 2-yr change) |